You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSotalol
Accession NumberDB00489  (APRD01230)
TypeSmall Molecule
GroupsApproved
DescriptionAn adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias. [PubChem]
Structure
Thumb
Synonyms
4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide
beta-Cardone
Sotalol
Sotalolo
Sotalolum
External Identifiers
  • MJ 1999
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-sotaloltablet80 mgoralAvanstra Inc2011-08-112014-08-21Canada
Ava-sotaloltablet160 mgoralAvanstra Inc2011-08-112014-08-21Canada
Betapacetablet80 mg/1oralBayer Health Care Pharmaceuticals Inc.1992-10-30Not applicableUs
Betapacetablet160 mg/1oralBayer Health Care Pharmaceuticals Inc.1992-10-30Not applicableUs
Betapacetablet120 mg/1oralBayer Health Care Pharmaceuticals Inc.1992-10-30Not applicableUs
Betapace AFtablet80 mg/1oralBayer Health Care Pharmaceuticals Inc.2000-02-22Not applicableUs
Betapace AFtablet160 mg/1oralBayer Health Care Pharmaceuticals Inc.2000-02-22Not applicableUs
Betapace AFtablet120 mg/1oralBayer Health Care Pharmaceuticals Inc.2000-02-22Not applicableUs
Co Sotaloltablet160 mgoralCobalt Pharmaceuticals Company2006-07-13Not applicableCanada
Co Sotaloltablet80 mgoralCobalt Pharmaceuticals Company2006-07-13Not applicableCanada
Dom-sotaloltablet80 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Dom-sotaloltablet160 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Ftp-sotaloltablet80 mgoralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Ftp-sotaloltablet160 mgoralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Gen-sotalol 240mgtablet240 mgoralGenpharm Ulc1996-10-212009-08-05Canada
Jamp-sotaloltablet80 mgoralJamp Pharma Corporation2011-10-20Not applicableCanada
Jamp-sotaloltablet160 mgoralJamp Pharma Corporation2011-10-20Not applicableCanada
Linsotalol - Tab 80mgtablet80 mgoralLinson Pharma Co.1995-12-312006-05-29Canada
Linsotalol -tab 160mgtablet160 mgoralLinson Pharma Co.1995-12-312006-05-29Canada
Med Sotaloltablet160 mgoralMedican Pharma Incorporated1998-02-052011-03-29Canada
Med Sotaloltablet80 mgoralMedican Pharma Incorporated1998-02-052011-03-29Canada
Mylan-sotaloltablet80 mgoralMylan Pharmaceuticals Ulc1996-10-21Not applicableCanada
Mylan-sotaloltablet160 mgoralMylan Pharmaceuticals Ulc1996-10-21Not applicableCanada
Novo-sotalol Tab 160mgtablet160 mgoralNovopharm Limited1997-05-132015-10-26Canada
Novo-sotalol Tab 80mgtablet80 mgoralNovopharm Limited1997-05-132015-10-26Canada
Nu-sotalol - Tab 160 mgtablet160 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Nu-sotalol - Tab 80mgtablet80 mgoralNu Pharm Inc1996-12-312012-09-04Canada
PHL-sotaloltablet80 mgoralPharmel Inc1998-12-01Not applicableCanada
PHL-sotaloltablet160 mgoralPharmel Inc1998-12-01Not applicableCanada
PMS-sotalol - 160 mgtablet160 mgoralPharmascience Inc1998-07-22Not applicableCanada
PMS-sotalol - 240 mgtablet240 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-sotalol - 80 mgtablet80 mgoralPharmascience Inc1998-07-22Not applicableCanada
Pro-sotaloltablet80 mgoralPro Doc Limitee2008-10-15Not applicableCanada
Pro-sotaloltablet160 mgoralPro Doc Limitee2008-10-15Not applicableCanada
Ratio-sotaloltablet80 mgoralTeva Canada Limited1995-12-31Not applicableCanada
Ratio-sotaloltablet160 mgoralTeva Canada Limited1995-12-31Not applicableCanada
Rho-sotaloltablet240 mgoralRhoxalpharma IncNot applicableNot applicableCanada
Rhoxal-sotaloltablet80 mgoralRhoxalpharma Inc1997-12-022009-11-24Canada
Rhoxal-sotaloltablet160 mgoralRhoxalpharma Inc1997-12-022009-11-24Canada
Riva-sotaloltablet160 mgoralLaboratoire Riva Inc2016-07-15Not applicableCanada
Riva-sotaloltablet80 mgoralLaboratoire Riva Inc2010-06-04Not applicableCanada
Riva-sotaloltablet160 mgoralLaboratoire Riva Inc2000-05-232016-07-15Canada
Riva-sotaloltablet80 mgoralLaboratoire Riva Inc2000-05-232013-07-31Canada
Rylosoltablet240 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
Rylosoltablet80 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
Rylosoltablet160 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
Sandoz Sotaloltablet80 mgoralSandoz Canada Incorporated2004-09-21Not applicableCanada
Sandoz Sotaloltablet160 mgoralSandoz Canada Incorporated2004-09-21Not applicableCanada
Sotacor Tab 160mgtablet160 mgoralBristol Labs Division Of Bristol Myers Squibb1985-12-312005-08-01Canada
Sotacor Tab 240mgtablet240 mgoralBristol Labs Division Of Bristol Myers Squibb1993-12-311996-09-09Canada
Sotacor Tab 80mgtablet80 mgoralBristol Labs Division Of Bristol Myers Squibb1993-12-312005-08-01Canada
Sotaloltablet80 mgoralSorres Pharma Inc2009-06-222014-06-20Canada
Sotaloltablet160 mgoralSorres Pharma Inc2009-06-222014-06-20Canada
Sotaloltablet80 mgoralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
Sotaloltablet160 mgoralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
Sotalol Hydrochlorideinjection15 mg/mLintravenousMylan Institutional LLC2009-09-30Not applicableUs
Sotalol Hydrochlorideinjection15 mg/mLintravenousAltathera Pharmaceuticals, Llc2015-10-15Not applicableUs
Sotalol-160 - Tab 160mgtablet160 mgoralPro Doc Limitee1997-01-152009-07-23Canada
Sotalol-80 - Tab 80mgtablet80 mgoralPro Doc Limitee1997-01-152010-07-13Canada
Sotamoltablet160 mgoralTechnilab Pharma Inc.1998-10-292006-07-28Canada
Sotamoltablet80 mgoralTechnilab Pharma Inc.1998-10-292006-07-28Canada
Sotylizesolution5 mg/mLoralArbor Pharmaceuticals, Inc.2015-03-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-sotalol - Tab 160mgtablet160 mgoralApotex Inc1995-12-31Not applicableCanada
Apo-sotalol 80mg Tabletstablet80 mgoralApotex Inc1996-12-31Not applicableCanada
Sorinetablet240 mg/1oralUpsher Smith Laboratories, Inc.2011-02-15Not applicableUs
Sorinetablet80 mg/1oralUpsher Smith Laboratories, Inc.2011-02-15Not applicableUs
Sorinetablet120 mg/1oralUpsher Smith Laboratories, Inc.2011-02-15Not applicableUs
Sorinetablet80 mg/1oralCardinal Health2011-02-15Not applicableUs
Sorinetablet160 mg/1oralUpsher Smith Laboratories, Inc.2011-02-15Not applicableUs
Sotalol Hydrochloridetablet240 mg/1oralQualitest Pharmaceuticals2003-11-07Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralGolden State Medical Supply, Inc.2003-09-09Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralbryant ranch prepack2003-11-07Not applicableUs
Sotalol Hydrochloridetablet240 mg/1oralGlobal Pharmaceuticals2000-11-07Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralTeva Pharmaceuticals USA Inc2000-05-05Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralAv Kare, Inc.2014-02-13Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralApotex Corp.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralEpic Pharma, LLC2016-01-04Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralEon Labs, Inc.2000-05-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralLake Erie Medical DBA Quality Care Products LLC2003-11-07Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralGolden State Medical Supply, Inc.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralAmerican Health Packaging2013-06-122016-01-01Us
Sotalol Hydrochloridetablet80 mg/1oralGlobal Pharmaceuticals2000-11-07Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralQualitest Pharmaceuticals2003-11-07Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralPhysicians Total Care, Inc.2006-03-14Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralApotex Corp.2003-09-09Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralEon Labs, Inc.2000-05-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-11-07Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralGolden State Medical Supply, Inc.2003-09-09Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralbryant ranch prepack2003-11-07Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralTeva Pharmaceuticals USA Inc2000-05-04Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralMylan Pharmaceuticals Inc.2007-02-20Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralPd Rx Pharmaceuticals, Inc.2000-05-01Not applicableUs
Sotalol Hydrochloridetablet240 mg/1oralApotex Corp.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralEpic Pharma, LLC2016-01-04Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralLake Erie Medical DBA Quality Care Products LLC2003-11-07Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralGolden State Medical Supply, Inc.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralGlobal Pharmaceuticals2000-11-07Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralQualitest Pharmaceuticals2003-11-07Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralPhysicians Total Care, Inc.2009-04-08Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralApotex Corp.2003-09-09Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralEon Labs, Inc.2000-05-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-02-01Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralGolden State Medical Supply, Inc.2003-09-09Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralAmerican Health Packaging2014-03-18Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralTeva Pharmaceuticals USA Inc2000-05-05Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralMylan Pharmaceuticals Inc.2007-02-20Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralAidarex Pharmaceuticals LLC2003-02-01Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralApotex Corp.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralAv Kare, Inc.2014-02-13Not applicableUs
Sotalol Hydrochloridetablet240 mg/1oralGolden State Medical Supply, Inc.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralGlobal Pharmaceuticals2000-11-07Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralQualitest Pharmaceuticals2003-11-07Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralProficient Rx LP2003-11-07Not applicableUs
Sotalol Hydrochloridetablet240 mg/1oralEon Labs, Inc.2000-05-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralRebel Distributors Corp2000-05-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralGolden State Medical Supply, Inc.2003-02-01Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralCarilion Materials Management2003-11-07Not applicableUs
Sotalol Hydrochloridetablet240 mg/1oralTeva Pharmaceuticals USA Inc2000-05-05Not applicableUs
Sotalol Hydrochloridetablet160 mg/1oralMylan Pharmaceuticals Inc.2007-02-20Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralPhysicians Total Care, Inc.2000-12-04Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralApotex Corp.2003-09-09Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralEpic Pharma, LLC2016-01-04Not applicableUs
Sotalol Hydrochloridetablet120 mg/1oralAv Kare, Inc.2014-02-13Not applicableUs
Sotalol Hydrochloridetablet80 mg/1oralApotex Corp.2003-02-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BiosotalSanofi-Aventis
CardolAlphapharm
DarobAbbott
Darob miteAbbott
HipecorMerck
LoritmikKrka
RytmobetaAbbott
SotacorBristol-Myers Squibb
SotagardGlaxoSmithKline
SotalexBristol-Myers Squibb
SotaporBristol-Myers Squibb
TalozinAdeka
Tan ShiChia Tai Tianqing
Xi An LinChangzhou Pharmaceutical Factory
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Sotalol Hydrochloride
959-24-0
Thumb
  • InChI Key: VIDRYROWYFWGSY-UHFFFAOYNA-N
  • Monoisotopic Mass: 308.096140945
  • Average Mass: 308.825
DBSALT000318
Categories
UNIIA6D97U294I
CAS number3930-20-9
WeightAverage: 272.364
Monoisotopic: 272.119463206
Chemical FormulaC12H20N2O3S
InChI KeyInChIKey=ZBMZVLHSJCTVON-UHFFFAOYSA-N
InChI
InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3
IUPAC Name
N-(4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}phenyl)methanesulfonamide
SMILES
CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfanilides. These are organic aromatic compounds containing a sulfanilide moiety, with the general structure RS(=O)(=O)NC1=CC=CC=C1.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassSulfanilides
Direct ParentSulfanilides
Alternative Parents
Substituents
  • Sulfanilide
  • Aralkylamine
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm. Also for the treatment of documented life-threatening ventricular arrhythmias.
PharmacodynamicsSotalol is an antiarrhythmic drug. It falls into the class of beta blockers (and class II antiarrhythmic agents) because of its primary action on the β-adrenergic receptors in the heart. In addition to its actions on the beta receptors in the heart, sotalol inhibits the inward potassium ion channels of the heart. In so doing, sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity. It also slows atrioventricular (AV) nodal conduction. Because of these actions on the cardiac action potential, it is also considered a class III antiarrhythmic agent. The beta-blocking effect of sotalol is non-cardioselective, half maximal at about 80mg/day and maximal at doses between 320 and 640 mg/day. Sotalol does not have partial agonist or membrane stabilizing activity. Although significant beta-blockade occurs at oral doses as low as 25 mg, significant Class Ieffects are seen only at daily doses of 160 mg and above.
Mechanism of actionSotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class I) and cardiac action potential duration prolongation (Vaughan Williams Class I) antiarrhythmic properties. Sotalol is a racemic mixture of d- and l-sotalol. Both isomers have similar Class I antiarrhythmic effects, while the l-isomer is responsible for virtually all of the beta-blocking activity. Sotalol inhibits response to adrenergic stimuli by competitively blocking β1-adrenergic receptors within the myocardium and β2-adrenergic receptors within bronchial and vascular smooth muscle. The electrophysiologic effects of sotalol may be due to its selective inhibition of the rapidly activating component of the potassium channel involved in the repolarization of cardiac cells. The class II electrophysiologic effects are caused by an increase in sinus cycle length (slowed heart rate), decreased AV nodal conduction, and increased AV nodal refractoriness, while the class III electrophysiological effects include prolongation of the atrial and ventricular monophasic action potentials, and effective refractory period prolongation of atrial muscle, ventricular muscle, and atrio-ventricular accessory pathways (where present) in both the anterograde and retrograde directions.
Related Articles
AbsorptionIn healthy subjects, the oral bioavailability of sotalol is 90-100%. Absorption is reduced by approximately 20% compared to fasting when administered with a standard meal.
Volume of distributionNot Available
Protein bindingSotalol does not bind to plasma proteins.
Metabolism

Sotalol is not metabolized.

Route of eliminationExcretion is predominantly via the kidney in the unchanged form. Sotalol is excreted in the milk of laboratory animals and has been reported to be present in human milk.
Half lifeMean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.
ClearanceNot Available
ToxicityThe most common signs to be expected are bradycardia, congestive heart failure, hypotension, bronchospasm and hypoglycemia. In cases of massive intentional overdosage (2-16 grams) of sotalol the following clinical findings were seen: hypotension, bradycardia, cardiac asystole, prolongation of QT interval, Torsade de Pointes, ventricular tachy-cardia, and premature ventricular complexes.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Sotalol Action PathwayDrug actionSMP00660
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.9382
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.6708
P-glycoprotein inhibitor INon-inhibitor0.8881
P-glycoprotein inhibitor IINon-inhibitor0.9638
Renal organic cation transporterNon-inhibitor0.9514
CYP450 2C9 substrateNon-substrate0.7392
CYP450 2D6 substrateNon-substrate0.8296
CYP450 3A4 substrateNon-substrate0.6194
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8807
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8276
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.587
BiodegradationNot ready biodegradable0.9949
Rat acute toxicity2.2873 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.846
hERG inhibition (predictor II)Non-inhibitor0.8701
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Academic pharmaceuticals inc
  • Bayer healthcare pharmaceuticals inc
  • Upsher smith laboratories inc
  • Amneal pharmaceutical
  • Apotex inc
  • Apotex inc etobicoke site
  • Impax pharmaceuticals
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral160 mg
Tabletoral80 mg
Tabletoral240 mg
Injectionintravenous15 mg/mL
Tabletoral120 mg/1
Tabletoral160 mg/1
Tabletoral240 mg/1
Tabletoral80 mg/1
Solutionoral5 mg/mL
Prices
Unit descriptionCostUnit
Betapace AF 100 160 mg tablet Box538.2USD box
Betapace AF 60 120 mg tablet Bottle311.06USD bottle
Betapace 240 mg tablet8.94USD tablet
Sotalol hcl 150 mg/10 ml vial7.8USD ml
Betapace 160 mg tablet6.87USD tablet
Betapace af 160 mg tablet6.24USD tablet
Sorine 240 mg tablet5.6USD tablet
Betapace 120 mg tablet5.5USD tablet
Sotalol HCl 240 mg tablet5.29USD tablet
Sotalol 240 mg tablet5.09USD tablet
Betapace af 120 mg tablet4.99USD tablet
Sotalol HCl (AF) 160 mg tablet4.45USD tablet
Sorine 160 mg tablet4.31USD tablet
Sotalol af 160 mg tablet4.27USD tablet
Betapace 80 mg tablet4.12USD tablet
Sotalol HCl 160 mg tablet4.07USD tablet
Sotalol 160 mg tablet3.92USD tablet
Betapace af 80 mg tablet3.74USD tablet
Sotalol HCl (AF) 120 mg tablet3.56USD tablet
Sorine 120 mg tablet3.46USD tablet
Sotalol af 120 mg tablet3.42USD tablet
Sotalol HCl 120 mg tablet3.26USD tablet
Sotalol 120 mg tablet3.13USD tablet
Sotalol HCl 80 mg tablet2.67USD tablet
Sotalol HCl (AF) 80 mg tablet2.67USD tablet
Sorine 80 mg tablet2.61USD tablet
Sotalol af 80 mg tablet2.56USD tablet
Sotalol 80 mg tablet2.35USD tablet
Apo-Sotalol 160 mg Tablet0.68USD tablet
Co Sotalol 160 mg Tablet0.68USD tablet
Mylan-Sotalol 160 mg Tablet0.68USD tablet
Novo-Sotalol 160 mg Tablet0.68USD tablet
Nu-Sotalol 160 mg Tablet0.68USD tablet
Pms-Sotalol 160 mg Tablet0.68USD tablet
Ratio-Sotalol 160 mg Tablet0.68USD tablet
Sandoz Sotalol 160 mg Tablet0.68USD tablet
Apo-Sotalol 80 mg Tablet0.62USD tablet
Co Sotalol 80 mg Tablet0.62USD tablet
Mylan-Sotalol 80 mg Tablet0.62USD tablet
Novo-Sotalol 80 mg Tablet0.62USD tablet
Nu-Sotalol 80 mg Tablet0.62USD tablet
Pms-Sotalol 80 mg Tablet0.62USD tablet
Ratio-Sotalol 80 mg Tablet0.62USD tablet
Sandoz Sotalol 80 mg Tablet0.62USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point206.5-207 °CPhysProp
water solubilitySoluble (5510 mg/L)Not Available
logP0.24BURGOT,G ET AL. (1990)
Predicted Properties
PropertyValueSource
Water Solubility0.782 mg/mLALOGPS
logP0.85ALOGPS
logP-0.4ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)10.07ChemAxon
pKa (Strongest Basic)9.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area78.43 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity71.12 m3·mol-1ChemAxon
Polarizability29.34 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996 Jul 6;348(9019):7-12. [PubMed:8691967 ]
External Links
ATC CodesC07AA57C07BA07C07AA07
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelDownload (93.8 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Sotalol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Sotalol.
AcebutololThe risk or severity of adverse effects can be increased when Sotalol is combined with Acebutolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Sotalol.
AcepromazineAcepromazine may increase the hypotensive activities of Sotalol.
AcetazolamideThe risk or severity of adverse effects can be increased when Sotalol is combined with Acetazolamide.
AcetohexamideSotalol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Sotalol is combined with Acetylcholine.
AcetyldigitoxinSotalol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Sotalol.
AdapaleneAdapalene may decrease the antihypertensive activities of Sotalol.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Sotalol.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sotalol.
AlfuzosinSotalol may increase the orthostatic hypotensive activities of Alfuzosin.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Sotalol.
AlimemazineAlimemazine may increase the hypotensive activities of Sotalol.
AliskirenThe risk or severity of adverse effects can be increased when Sotalol is combined with Aliskiren.
Aluminum hydroxideThe serum concentration of Sotalol can be decreased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Sotalol can be decreased when it is combined with Aluminum phosphate.
AmantadineAmantadine may increase the QTc-prolonging activities of Sotalol.
AmbenoniumAmbenonium may increase the bradycardic activities of Sotalol.
AmilorideThe risk or severity of adverse effects can be increased when Sotalol is combined with Amiloride.
AminophyllineSotalol may decrease the bronchodilatory activities of Aminophylline.
AmiodaroneSotalol may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Sotalol.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Sotalol.
AmobarbitalAmobarbital may increase the hypotensive activities of Sotalol.
AmodiaquineThe metabolism of Sotalol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Sotalol can be increased when it is combined with Amoxapine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Sotalol is combined with Amyl Nitrite.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Sotalol.
AntipyrineAntipyrine may decrease the antihypertensive activities of Sotalol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Sotalol.
ApraclonidineThe risk or severity of adverse effects can be increased when Sotalol is combined with Apraclonidine.
ApremilastApremilast may decrease the antihypertensive activities of Sotalol.
ArbutamineSotalol may decrease the bronchodilatory activities of Arbutamine.
ArecolineThe risk or severity of adverse effects can be increased when Sotalol is combined with Arecoline.
ArformoterolSotalol may decrease the bronchodilatory activities of Arformoterol.
ArformoterolArformoterol may increase the QTc-prolonging activities of Sotalol.
AripiprazoleAripiprazole may increase the hypotensive activities of Sotalol.
Arsenic trioxideSotalol may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherSotalol may increase the QTc-prolonging activities of Artemether.
AsenapineSotalol may increase the QTc-prolonging activities of Asenapine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Sotalol.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Sotalol.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Sotalol.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Sotalol.
AzelastineAzelastine may decrease the antihypertensive activities of Sotalol.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Sotalol is combined with Azilsartan medoxomil.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Sotalol.
BalsalazideBalsalazide may decrease the antihypertensive activities of Sotalol.
BambuterolSotalol may decrease the bronchodilatory activities of Bambuterol.
BarbitalBarbital may increase the hypotensive activities of Sotalol.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Sotalol.
BenazeprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Benazepril.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sotalol.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Sotalol.
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Sotalol.
BeractantSotalol may increase the bradycardic activities of Beractant.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Sotalol.
BethanecholThe risk or severity of adverse effects can be increased when Sotalol is combined with Bethanechol.
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Sotalol.
Bismuth SubcitrateThe serum concentration of Sotalol can be decreased when it is combined with Bismuth Subcitrate.
BisoprololThe risk or severity of adverse effects can be increased when Sotalol is combined with Bisoprolol.
BortezomibBortezomib may increase the QTc-prolonging activities of Sotalol.
BretyliumBretylium may increase the bradycardic activities of Sotalol.
BretyliumThe risk or severity of adverse effects can be increased when Sotalol is combined with Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Sotalol.
BromfenacBromfenac may decrease the antihypertensive activities of Sotalol.
BromocriptineSotalol may increase the vasoconstricting activities of Bromocriptine.
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Sotalol.
BumetanideThe risk or severity of adverse effects can be increased when Sotalol is combined with Bumetanide.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Sotalol.
BuserelinBuserelin may increase the QTc-prolonging activities of Sotalol.
CabergolineSotalol may increase the vasoconstricting activities of Cabergoline.
Calcium carbonateThe serum concentration of Sotalol can be decreased when it is combined with Calcium carbonate.
CalfactantSotalol may increase the bradycardic activities of Calfactant.
CanagliflozinThe risk or severity of adverse effects can be increased when Sotalol is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Candesartan.
CaptoprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Captopril.
CarbacholThe risk or severity of adverse effects can be increased when Sotalol is combined with Carbachol.
CarprofenCarprofen may decrease the antihypertensive activities of Sotalol.
CarteololThe risk or severity of adverse effects can be increased when Sotalol is combined with Carteolol.
CarvedilolThe risk or severity of adverse effects can be increased when Sotalol is combined with Carvedilol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Sotalol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Sotalol.
CeliprololSotalol may decrease the bronchodilatory activities of Celiprolol.
CeritinibSotalol may increase the bradycardic activities of Ceritinib.
CeritinibCeritinib may increase the QTc-prolonging activities of Sotalol.
CevimelineThe risk or severity of adverse effects can be increased when Sotalol is combined with Cevimeline.
ChloroquineChloroquine may increase the QTc-prolonging activities of Sotalol.
ChlorothiazideThe risk or severity of adverse effects can be increased when Sotalol is combined with Chlorothiazide.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Sotalol.
ChlorpropamideSotalol may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sotalol.
CilazaprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Cilazapril.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Sotalol.
CisaprideSotalol may increase the QTc-prolonging activities of Cisapride.
CitalopramCitalopram may increase the QTc-prolonging activities of Sotalol.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Sotalol.
ClenbuterolSotalol may decrease the bronchodilatory activities of Clenbuterol.
ClevidipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Clevidipine.
ClomipramineThe serum concentration of Sotalol can be increased when it is combined with Clomipramine.
ClonidineThe risk or severity of adverse effects can be increased when Sotalol is combined with Clonidine.
ClonixinClonixin may decrease the antihypertensive activities of Sotalol.
ClozapineClozapine may increase the QTc-prolonging activities of Sotalol.
CoumaphosCoumaphos may increase the bradycardic activities of Sotalol.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Sotalol.
CrizotinibSotalol may increase the bradycardic activities of Crizotinib.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Sotalol.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Sotalol.
DapagliflozinThe risk or severity of adverse effects can be increased when Sotalol is combined with Dapagliflozin.
DapoxetineThe serum concentration of Sotalol can be increased when it is combined with Dapoxetine.
DasatinibDasatinib may increase the QTc-prolonging activities of Sotalol.
DecamethoniumDecamethonium may increase the bradycardic activities of Sotalol.
DegarelixDegarelix may increase the QTc-prolonging activities of Sotalol.
DemecariumDemecarium may increase the bradycardic activities of Sotalol.
DesfluraneDesflurane may increase the QTc-prolonging activities of Sotalol.
DesipramineDesipramine may increase the QTc-prolonging activities of Sotalol.
DeslanosideSotalol may increase the bradycardic activities of Deslanoside.
DexmedetomidineThe risk or severity of adverse effects can be increased when Sotalol is combined with Dexmedetomidine.
DichlorvosDichlorvos may increase the bradycardic activities of Sotalol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Sotalol.
DiclofenamideThe risk or severity of adverse effects can be increased when Sotalol is combined with Diclofenamide.
DiflunisalDiflunisal may decrease the antihypertensive activities of Sotalol.
DigitoxinSotalol may increase the bradycardic activities of Digitoxin.
DigoxinSotalol may increase the bradycardic activities of Digoxin.
DihydroergotamineSotalol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Sotalol.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Sotalol.
DinutuximabThe risk or severity of adverse effects can be increased when Sotalol is combined with Dinutuximab.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Sotalol.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Sotalol.
DipivefrinSotalol may decrease the bronchodilatory activities of Dipivefrin.
DipyridamoleDipyridamole may increase the bradycardic activities of Sotalol.
DipyridamoleThe risk or severity of adverse effects can be increased when Sotalol is combined with Dipyridamole.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Sotalol.
DobutamineSotalol may decrease the bronchodilatory activities of Dobutamine.
DofetilideDofetilide may increase the QTc-prolonging activities of Sotalol.
DolasetronDolasetron may increase the QTc-prolonging activities of Sotalol.
DomperidoneSotalol may increase the QTc-prolonging activities of Domperidone.
DonepezilDonepezil may increase the bradycardic activities of Sotalol.
DoxazosinThe risk or severity of adverse effects can be increased when Sotalol is combined with Doxazosin.
DoxepinDoxepin may increase the QTc-prolonging activities of Sotalol.
DronedaroneSotalol may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Sotalol.
DroxicamDroxicam may decrease the antihypertensive activities of Sotalol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Sotalol.
DroxidopaSotalol may decrease the bronchodilatory activities of Droxidopa.
DuloxetineSotalol may increase the orthostatic hypotensive activities of Duloxetine.
DyphyllineSotalol may decrease the bronchodilatory activities of Dyphylline.
EchothiophateEchothiophate may increase the bradycardic activities of Sotalol.
EdrophoniumEdrophonium may increase the bradycardic activities of Sotalol.
EliglustatSotalol may increase the QTc-prolonging activities of Eliglustat.
EmpagliflozinThe risk or severity of adverse effects can be increased when Sotalol is combined with Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Enalapril.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Sotalol.
EphedraSotalol may decrease the bronchodilatory activities of Ephedra.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Sotalol is combined with EPIBATIDINE.
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Sotalol.
EpinephrineSotalol may decrease the bronchodilatory activities of Epinephrine.
EpirizoleEpirizole may decrease the antihypertensive activities of Sotalol.
EplerenoneThe risk or severity of adverse effects can be increased when Sotalol is combined with Eplerenone.
EprosartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Eprosartan.
Ergoloid mesylateSotalol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovineSotalol may increase the vasoconstricting activities of Ergonovine.
ErgotamineSotalol may increase the vasoconstricting activities of Ergotamine.
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Sotalol.
EribulinEribulin may increase the QTc-prolonging activities of Sotalol.
ErythromycinErythromycin may increase the QTc-prolonging activities of Sotalol.
EscitalopramSotalol may increase the QTc-prolonging activities of Escitalopram.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Sotalol.
Etacrynic acidThe risk or severity of adverse effects can be increased when Sotalol is combined with Etacrynic acid.
EtanerceptEtanercept may decrease the antihypertensive activities of Sotalol.
EtodolacEtodolac may decrease the antihypertensive activities of Sotalol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Sotalol.
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Sotalol.
EtoperidoneThe serum concentration of Sotalol can be increased when it is combined with Etoperidone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Sotalol.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Sotalol.
exisulindexisulind may decrease the antihypertensive activities of Sotalol.
EzogabineEzogabine may increase the QTc-prolonging activities of Sotalol.
FamotidineFamotidine may increase the QTc-prolonging activities of Sotalol.
FelbamateFelbamate may increase the QTc-prolonging activities of Sotalol.
FelodipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Felodipine.
FenbufenFenbufen may decrease the antihypertensive activities of Sotalol.
FenfluramineThe serum concentration of Sotalol can be increased when it is combined with Fenfluramine.
FenoprofenFenoprofen may decrease the antihypertensive activities of Sotalol.
FenoterolSotalol may decrease the bronchodilatory activities of Fenoterol.
FenthionFenthion may increase the bradycardic activities of Sotalol.
FingolimodSotalol may increase the bradycardic activities of Fingolimod.
FlecainideFlecainide may increase the QTc-prolonging activities of Sotalol.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Sotalol.
FluconazoleFluconazole may increase the QTc-prolonging activities of Sotalol.
FlunixinFlunixin may decrease the antihypertensive activities of Sotalol.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Sotalol.
FlupentixolSotalol may increase the QTc-prolonging activities of Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Sotalol.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Sotalol.
FormoterolSotalol may decrease the bronchodilatory activities of Formoterol.
FormoterolFormoterol may increase the QTc-prolonging activities of Sotalol.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Sotalol.
FosinoprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Fosinopril.
FurosemideThe risk or severity of adverse effects can be increased when Sotalol is combined with Furosemide.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Sotalol.
GalantamineGalantamine may increase the bradycardic activities of Sotalol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Sotalol.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Sotalol.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Sotalol.
GlibornurideSotalol may increase the hypoglycemic activities of Glibornuride.
GliclazideSotalol may increase the hypoglycemic activities of Gliclazide.
GlimepirideSotalol may increase the hypoglycemic activities of Glimepiride.
GlipizideSotalol may increase the hypoglycemic activities of Glipizide.
GliquidoneSotalol may increase the hypoglycemic activities of Gliquidone.
GlisoxepideSotalol may increase the hypoglycemic activities of Glisoxepide.
GlyburideSotalol may increase the hypoglycemic activities of Glyburide.
GoserelinGoserelin may increase the QTc-prolonging activities of Sotalol.
GranisetronGranisetron may increase the QTc-prolonging activities of Sotalol.
GTS-21The risk or severity of adverse effects can be increased when Sotalol is combined with GTS-21.
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Sotalol.
GuanfacineThe risk or severity of adverse effects can be increased when Sotalol is combined with Guanfacine.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Sotalol.
HexobarbitalHexobarbital may increase the hypotensive activities of Sotalol.
HistrelinHistrelin may increase the QTc-prolonging activities of Sotalol.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Sotalol.
Huperzine AHuperzine A may increase the bradycardic activities of Sotalol.
HydralazineThe risk or severity of adverse effects can be increased when Sotalol is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Sotalol is combined with Hydrochlorothiazide.
HydroxychloroquineThe metabolism of Sotalol can be decreased when combined with Hydroxychloroquine.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Sotalol.
IbandronateIbandronate may increase the QTc-prolonging activities of Sotalol.
IbuprofenIbuprofen may decrease the antihypertensive activities of Sotalol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Sotalol.
IbutilideIbutilide may increase the QTc-prolonging activities of Sotalol.
IcatibantIcatibant may decrease the antihypertensive activities of Sotalol.
IloperidoneSotalol may increase the QTc-prolonging activities of Iloperidone.
ImipramineImipramine may increase the QTc-prolonging activities of Sotalol.
IndacaterolSotalol may decrease the bronchodilatory activities of Indacaterol.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Sotalol.
IndalpineThe serum concentration of Sotalol can be increased when it is combined with Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Sotalol is combined with Indapamide.
IndomethacinIndomethacin may decrease the antihypertensive activities of Sotalol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Sotalol.
IndoraminSotalol may increase the orthostatic hypotensive activities of Indoramin.
Insulin PorkSotalol may increase the hypoglycemic activities of Insulin Pork.
IrbesartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Irbesartan.
IsoetarineSotalol may decrease the bronchodilatory activities of Isoetarine.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Sotalol.
IsoflurophateIsoflurophate may increase the bradycardic activities of Sotalol.
IsoprenalineSotalol may decrease the bronchodilatory activities of Isoprenaline.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Sotalol is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Sotalol is combined with Isosorbide Mononitrate.
IsoxicamIsoxicam may decrease the antihypertensive activities of Sotalol.
IsoxsuprineThe risk or severity of adverse effects can be increased when Sotalol is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Sotalol.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Sotalol.
IvabradineSotalol may increase the bradycardic activities of Ivabradine.
IvabradineIvabradine may increase the QTc-prolonging activities of Sotalol.
KebuzoneKebuzone may decrease the antihypertensive activities of Sotalol.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Sotalol.
KetoprofenKetoprofen may decrease the antihypertensive activities of Sotalol.
KetorolacKetorolac may decrease the antihypertensive activities of Sotalol.
LabetalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Labetalol.
LacosamideSotalol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LanreotideSotalol may increase the bradycardic activities of Lanreotide.
LapatinibLapatinib may increase the QTc-prolonging activities of Sotalol.
LeflunomideLeflunomide may decrease the antihypertensive activities of Sotalol.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Sotalol.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Sotalol.
LevobunololThe risk or severity of adverse effects can be increased when Sotalol is combined with Levobunolol.
LevodopaSotalol may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Sotalol.
LevomilnacipranThe serum concentration of Sotalol can be increased when it is combined with Levomilnacipran.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Sotalol.
LisinoprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Lisinopril.
LithiumLithium may increase the QTc-prolonging activities of Sotalol.
LobelineThe risk or severity of adverse effects can be increased when Sotalol is combined with Lobeline.
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Sotalol.
LopinavirSotalol may increase the QTc-prolonging activities of Lopinavir.
LornoxicamLornoxicam may decrease the antihypertensive activities of Sotalol.
LosartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Losartan.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Sotalol.
Lu AA21004The serum concentration of Sotalol can be increased when it is combined with Lu AA21004.
LucinactantSotalol may increase the bradycardic activities of Lucinactant.
LumefantrineSotalol may increase the QTc-prolonging activities of Lumefantrine.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Sotalol.
MagaldrateThe serum concentration of Sotalol can be decreased when it is combined with Magaldrate.
Magnesium carbonateThe serum concentration of Sotalol can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Sotalol can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Sotalol can be decreased when it is combined with Magnesium oxide.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Sotalol.
Magnesium TrisilicateThe serum concentration of Sotalol can be decreased when it is combined with Magnesium Trisilicate.
MalathionMalathion may increase the bradycardic activities of Sotalol.
MannitolThe risk or severity of adverse effects can be increased when Sotalol is combined with Mannitol.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Sotalol.
MasoprocolMasoprocol may decrease the antihypertensive activities of Sotalol.
MecamylamineThe risk or severity of adverse effects can be increased when Sotalol is combined with Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Sotalol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Sotalol.
MefloquineMefloquine may increase the bradycardic activities of Sotalol.
MeloxicamMeloxicam may decrease the antihypertensive activities of Sotalol.
MemantineMemantine may increase the bradycardic activities of Sotalol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Sotalol.
MesalazineMesalazine may decrease the antihypertensive activities of Sotalol.
MesoridazineMesoridazine may increase the hypotensive activities of Sotalol.
MetamizoleMetamizole may decrease the antihypertensive activities of Sotalol.
MethacholineThe risk or severity of adverse effects can be increased when Sotalol is combined with Methacholine.
MethadoneMethadone may increase the QTc-prolonging activities of Sotalol.
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Sotalol.
MethazolamideThe risk or severity of adverse effects can be increased when Sotalol is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Sotalol.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Sotalol.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sotalol.
MethyldopaThe risk or severity of adverse effects can be increased when Sotalol is combined with Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Sotalol.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Sotalol.
MetipranololThe risk or severity of adverse effects can be increased when Sotalol is combined with Metipranolol.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Sotalol.
MetolazoneThe risk or severity of adverse effects can be increased when Sotalol is combined with Metolazone.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Sotalol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Sotalol.
MidodrineSotalol may increase the bradycardic activities of Midodrine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Sotalol.
MilnacipranThe serum concentration of Sotalol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Sotalol.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Sotalol.
MirabegronMirabegron may increase the QTc-prolonging activities of Sotalol.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Sotalol.
MoexiprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Moexipril.
MoricizineMoricizine may increase the hypotensive activities of Sotalol.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Sotalol.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Sotalol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Sotalol.
NabumetoneNabumetone may decrease the antihypertensive activities of Sotalol.
NadololThe risk or severity of adverse effects can be increased when Sotalol is combined with Nadolol.
NaftifineNaftifine may decrease the antihypertensive activities of Sotalol.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Sotalol.
NaproxenNaproxen may decrease the antihypertensive activities of Sotalol.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Sotalol.
NebivololThe risk or severity of adverse effects can be increased when Sotalol is combined with Nebivolol.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Sotalol.
NeostigmineNeostigmine may increase the bradycardic activities of Sotalol.
NepafenacNepafenac may decrease the antihypertensive activities of Sotalol.
NesiritideThe risk or severity of adverse effects can be increased when Sotalol is combined with Nesiritide.
NicardipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Sotalol.
NicotineThe risk or severity of adverse effects can be increased when Sotalol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Sotalol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Sotalol.
NifedipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Sotalol.
NilotinibSotalol may increase the QTc-prolonging activities of Nilotinib.
NimesulideNimesulide may decrease the antihypertensive activities of Sotalol.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Sotalol.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Sotalol.
NitroglycerinThe risk or severity of adverse effects can be increased when Sotalol is combined with Nitroglycerin.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Sotalol.
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Sotalol.
NorepinephrineSotalol may decrease the bronchodilatory activities of Norepinephrine.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Sotalol.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Sotalol.
OctreotideOctreotide may increase the bradycardic activities of Sotalol.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Sotalol.
OlanzapineThe serum concentration of Sotalol can be increased when it is combined with Olanzapine.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sotalol.
OlodaterolSotalol may decrease the bronchodilatory activities of Olodaterol.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Sotalol.
OlopatadineOlopatadine may decrease the antihypertensive activities of Sotalol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Sotalol.
OndansetronOndansetron may increase the QTc-prolonging activities of Sotalol.
OrciprenalineSotalol may decrease the bronchodilatory activities of Orciprenaline.
OrgoteinOrgotein may decrease the antihypertensive activities of Sotalol.
OuabainSotalol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Sotalol.
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Sotalol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Sotalol.
OxytocinOxytocin may increase the QTc-prolonging activities of Sotalol.
PaliperidoneSotalol may increase the QTc-prolonging activities of Paliperidone.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Sotalol.
PapaverineThe risk or severity of adverse effects can be increased when Sotalol is combined with Papaverine.
ParecoxibParecoxib may decrease the antihypertensive activities of Sotalol.
ParoxetineThe serum concentration of Sotalol can be increased when it is combined with Paroxetine.
PasireotideSotalol may increase the bradycardic activities of Pasireotide.
PazopanibPazopanib may increase the QTc-prolonging activities of Sotalol.
PenbutololThe risk or severity of adverse effects can be increased when Sotalol is combined with Penbutolol.
PentamidinePentamidine may increase the QTc-prolonging activities of Sotalol.
PentobarbitalPentobarbital may increase the hypotensive activities of Sotalol.
PerflutrenPerflutren may increase the QTc-prolonging activities of Sotalol.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Sotalol.
PerindoprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Perindopril.
PerphenazinePerphenazine may increase the hypotensive activities of Sotalol.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Sotalol.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Sotalol.
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Sotalol.
PhenylpropanolamineSotalol may decrease the bronchodilatory activities of Phenylpropanolamine.
PhysostigminePhysostigmine may increase the bradycardic activities of Sotalol.
PilocarpineThe risk or severity of adverse effects can be increased when Sotalol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Sotalol.
PimozideSotalol may increase the QTc-prolonging activities of Pimozide.
PindololThe risk or severity of adverse effects can be increased when Sotalol is combined with Pindolol.
PirbuterolSotalol may decrease the bronchodilatory activities of Pirbuterol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Sotalol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Sotalol.
Poractant alfaSotalol may increase the bradycardic activities of Poractant alfa.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Sotalol.
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Sotalol.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Sotalol.
PrimidonePrimidone may increase the hypotensive activities of Sotalol.
ProcainamideSotalol may increase the QTc-prolonging activities of Procainamide.
ProcaterolSotalol may decrease the bronchodilatory activities of Procaterol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Sotalol.
PromazinePromazine may increase the QTc-prolonging activities of Sotalol.
PromethazinePromethazine may increase the hypotensive activities of Sotalol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Sotalol.
PropafenonePropafenone may increase the QTc-prolonging activities of Sotalol.
PropafenoneSotalol may increase the bradycardic activities of Propafenone.
PropofolPropofol may increase the QTc-prolonging activities of Sotalol.
PropranololThe risk or severity of adverse effects can be increased when Sotalol is combined with Propranolol.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Sotalol.
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Sotalol.
PTC299PTC299 may decrease the antihypertensive activities of Sotalol.
PyridostigminePyridostigmine may increase the bradycardic activities of Sotalol.
QuetiapineSotalol may increase the QTc-prolonging activities of Quetiapine.
QuinaprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Quinapril.
QuinidineSotalol may increase the QTc-prolonging activities of Quinidine.
QuinineQuinine may increase the QTc-prolonging activities of Sotalol.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Sotalol.
RanolazineRanolazine may increase the QTc-prolonging activities of Sotalol.
RegorafenibRegorafenib may increase the bradycardic activities of Sotalol.
ReserpineReserpine may increase the hypotensive activities of Sotalol.
ReserpineThe risk or severity of adverse effects can be increased when Sotalol is combined with Reserpine.
ResveratrolResveratrol may decrease the antihypertensive activities of Sotalol.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Sotalol.
RiociguatThe risk or severity of adverse effects can be increased when Sotalol is combined with Riociguat.
RisperidoneSotalol may increase the hypotensive activities of Risperidone.
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Sotalol.
RitodrineSotalol may decrease the bronchodilatory activities of Ritodrine.
RitonavirRitonavir may increase the QTc-prolonging activities of Sotalol.
RivastigmineRivastigmine may increase the bradycardic activities of Sotalol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Sotalol.
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Sotalol.
RuxolitinibRuxolitinib may increase the bradycardic activities of Sotalol.
SalbutamolSotalol may decrease the bronchodilatory activities of Salbutamol.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Sotalol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Sotalol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Sotalol.
SalmeterolSotalol may decrease the bronchodilatory activities of Salmeterol.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Sotalol.
SalsalateSalsalate may decrease the antihypertensive activities of Sotalol.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Sotalol.
SecobarbitalSecobarbital may increase the hypotensive activities of Sotalol.
SeratrodastSeratrodast may decrease the antihypertensive activities of Sotalol.
SertralineThe serum concentration of Sotalol can be increased when it is combined with Sertraline.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Sotalol.
SilodosinSotalol may increase the orthostatic hypotensive activities of Silodosin.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Sotalol.
SorafenibSorafenib may increase the QTc-prolonging activities of Sotalol.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Sotalol.
SRT501SRT501 may decrease the antihypertensive activities of Sotalol.
SufentanilSotalol may increase the bradycardic activities of Sufentanil.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Sotalol.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Sotalol.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Sotalol.
SulindacSulindac may decrease the antihypertensive activities of Sotalol.
SunitinibSunitinib may increase the QTc-prolonging activities of Sotalol.
SuprofenSuprofen may decrease the antihypertensive activities of Sotalol.
TacrineTacrine may increase the bradycardic activities of Sotalol.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Sotalol.
TamsulosinSotalol may increase the orthostatic hypotensive activities of Tamsulosin.
TelavancinTelavancin may increase the QTc-prolonging activities of Sotalol.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Sotalol.
TelmisartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Telmisartan.
TenoxicamTenoxicam may decrease the antihypertensive activities of Sotalol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Sotalol.
TerazosinThe risk or severity of adverse effects can be increased when Sotalol is combined with Terazosin.
TerbutalineSotalol may decrease the bronchodilatory activities of Terbutaline.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Sotalol.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Sotalol.
TetrabenazineSotalol may increase the QTc-prolonging activities of Tetrabenazine.
TheophyllineSotalol may decrease the bronchodilatory activities of Theophylline.
ThiamylalThiamylal may increase the hypotensive activities of Sotalol.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Sotalol.
ThiopentalThiopental may increase the hypotensive activities of Sotalol.
ThioridazineSotalol may increase the QTc-prolonging activities of Thioridazine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Sotalol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Sotalol.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Sotalol.
TizanidineThe risk or severity of adverse effects can be increased when Sotalol is combined with Tizanidine.
TofacitinibTofacitinib may increase the bradycardic activities of Sotalol.
TolazamideSotalol may increase the hypoglycemic activities of Tolazamide.
TolbutamideSotalol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Sotalol.
TolmetinTolmetin may decrease the antihypertensive activities of Sotalol.
TolterodineTolterodine may increase the QTc-prolonging activities of Sotalol.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Sotalol.
ToremifeneSotalol may increase the QTc-prolonging activities of Toremifene.
TrandolaprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Trandolapril.
TranilastTranilast may decrease the antihypertensive activities of Sotalol.
TrazodoneThe serum concentration of Sotalol can be increased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Sotalol.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Sotalol.
TrichlorfonTrichlorfon may increase the bradycardic activities of Sotalol.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Sotalol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Sotalol.
TrimazosinSotalol may increase the orthostatic hypotensive activities of Trimazosin.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Sotalol.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Sotalol.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Sotalol.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Sotalol.
TubocurarineTubocurarine may increase the bradycardic activities of Sotalol.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Sotalol.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Sotalol.
VandetanibSotalol may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Sotalol.
VareniclineThe risk or severity of adverse effects can be increased when Sotalol is combined with Varenicline.
VemurafenibSotalol may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Sotalol.
VerapamilThe risk or severity of adverse effects can be increased when Sotalol is combined with Verapamil.
VilanterolSotalol may decrease the bronchodilatory activities of Vilanterol.
VilanterolVilanterol may increase the QTc-prolonging activities of Sotalol.
VilazodoneThe serum concentration of Sotalol can be increased when it is combined with Vilazodone.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Sotalol.
VorinostatVorinostat may increase the QTc-prolonging activities of Sotalol.
VortioxetineThe serum concentration of Sotalol can be increased when it is combined with Vortioxetine.
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Sotalol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Sotalol.
ZileutonZileuton may decrease the antihypertensive activities of Sotalol.
ZimelidineThe serum concentration of Sotalol can be increased when it is combined with Zimelidine.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Sotalol.
ZomepiracZomepirac may decrease the antihypertensive activities of Sotalol.
ZuclopenthixolSotalol may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Shimizu W, Antzelevitch C: Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation. 2000 Aug 8;102(6):706-12. [PubMed:10931813 ]
  2. Numaguchi H, Mullins FM, Johnson JP Jr, Johns DC, Po SS, Yang IC, Tomaselli GF, Balser JR: Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ Res. 2000 Nov 24;87(11):1012-8. [PubMed:11090546 ]
  3. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R, Brugada R, Hong K, Bauersfeld U, Gaita F, Borggrefe M: Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. [PubMed:15673388 ]
  4. Wolpert C, Schimpf R, Veltmann C, Giustetto C, Gaita F, Borggrefe M: Clinical characteristics and treatment of short QT syndrome. Expert Rev Cardiovasc Ther. 2005 Jul;3(4):611-7. [PubMed:16076272 ]
  5. Fedida D, Orth PM, Hesketh JC, Ezrin AM: The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol. 2006 May;17 Suppl 1:S71-S78. [PubMed:16686685 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Lowe MD, Lynham JA, Grace AA, Kaumann AJ: Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol. 2002 Jan;135(2):451-61. [PubMed:11815381 ]
  2. Joseph SS, Lynham JA, Colledge WH, Kaumann AJ: Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32. Epub 2004 Apr 2. [PubMed:15060759 ]
  3. Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L, Freund-Mercier MJ, Barrot M: beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25. doi: 10.1002/ana.21542. [PubMed:19259968 ]
  4. Doggrell SA: The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein. Chirality. 1993;5(1):8-14. [PubMed:8095397 ]
  5. Juberg EN, Minneman KP, Abel PW: Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):193-202. [PubMed:2865685 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Lowe MD, Lynham JA, Grace AA, Kaumann AJ: Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol. 2002 Jan;135(2):451-61. [PubMed:11815381 ]
  2. Joseph SS, Lynham JA, Colledge WH, Kaumann AJ: Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32. Epub 2004 Apr 2. [PubMed:15060759 ]
  3. Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L, Freund-Mercier MJ, Barrot M: beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25. doi: 10.1002/ana.21542. [PubMed:19259968 ]
  4. Doggrell SA: The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein. Chirality. 1993;5(1):8-14. [PubMed:8095397 ]
  5. Juberg EN, Minneman KP, Abel PW: Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):193-202. [PubMed:2865685 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23